

A woman wearing a light blue headscarf and a matching short-sleeved shirt is sitting on a white couch. She is looking upwards and to the right with a gentle smile. Her arms are crossed over her knees.

**IndiTreat® - Functional Precision Medicine for  
matching cancer patients with the best treatment**

**Company  
presentation  
July 2020**

## Agenda

- 2cureX in brief
- The IndiTreat® test
- Partners
- Market and market potential
- Highlights 2019 and 2020
- The Management Team
- The Board of Directors
- Financials
- Expectation and outlook towards launch in 2020
- Why invest

- because cancer patients are individuals



## - Improving patient outcome



## 2cureX in brief:

- 2cureX is a European biotechnology company listed on NASDAQ First North Growth Market (Stockholm)
- 2cureX's proprietary IndiTreat® test will find the best treatment for each cancer patient
- 2cureX is conducting Clinical Trials in Colorectal, Ovarian and Pancreatic Cancer
- 2cureX has partnering hospitals and a distributor network in place

- because cancer patients are individuals

**2cureX**




Movie can be found on 2cureX's website  
(<https://www.2curex.com/products/inditreat-test/>)

# Problem: Drug therapy in cancer often fails

---

*Ernst and Young report*



On average the percentage of the population for whom a particular drug in a specific disease area was ineffective

- because cancer patients are individuals

# A one size fits all approach is not the solution

---

## Guideline Drug Therapies



Standard



## Genomic Precision Medicine



Personal



- because cancer patients are individuals




# Is Genomic Precision Medicine the answer?

**HOWEVER: UNTIL NOW, NO  
CONVINCING BENEFIT FROM LARGE  
SCALE TUMOUR AGNOSTIC STUDIES**

11 trials, including more than 13,000 patients

Various gene panels (including 49-87 genes) and tissue microarrays



Tannock IF & Hickman JA, Ann Oncol 2019, 30(5): 661-663

Genomic Precision Medicine helps only a small subset of patients


- because cancer patients are individuals

# IndiTreat® is needed for achieving individualized cancer treatment

## Guideline Drug Therapies




Standard



## Functional Precision Medicine

IndiTreat®




## Genomic Precision Medicine



- because cancer patients are individuals




# IndiTreat® expands precision medicine beyond genomics




**Cancer  
Diagnosis**


**Surgery or Biopsy**



**IndiTreat®**



**Molecular  
Tumor Board**




**Treatment  
decision**

- because cancer patients are individuals

# IndiTreat®, the Functional Precision Medicine Test

IndiTreat® is matching a patient's tumor to an effective treatment



**2cureX**  
**3D- Micro Tumor**

## Patient-derived tumoroids


- Mimic the biological features of the primary tumor
- Maintain cell-cell and cell-matrix interactions
- Replicate the tumor microenvironment

- because cancer patients are individuals

# IndiTreat® identifies the best treatment

The Functional Precision Medicine (FPM) test IndiTreat® measures drug sensitivity and resistance in each cancer patient

100s to 1000s copies (tumoroids) are generated from a patient's tumor. The tumoroids correspond to the parent tumor of the patient



*Tumoroids grow as in the patient*


*Tumor is resistant to Treatment A*

*Treatment B is highly effective – will be provided to patient*

CE

- because cancer patients are individuals

# IndiTreat® finds both effective and non-effective treatments



- because cancer patients are individuals

# IndiTreat® Clinical results

Interim analysis: efficacy and technical endpoints were fulfilled



## Primary endpoint (efficacy):

60% of patients treated according to IndiTreat® showed progression-free-survival (PFS) at the 8-week CT scan. Historical data: <20%.



## Secondary endpoint (technical):

From 70% of the patients, microtumors were successfully generated from liver biopsies and drug screening conducted.  
Cut-off: >50%.



Trial will continue towards conclusion in Q3 2020.

Lars Henrik Jensen; Chief Oncologist  
University Hospital Vejle  
(Chairman of Danish Soc. Clin. Oncology)



*“The present data showed that  
it is feasible to tailor-make  
treatment using a functional  
test like IndiTreat®”*



Funded by the Horizon 2020  
Framework Programme of the  
European Union

- because cancer patients are individuals

2cureX



## IndiTreat® in three major cancers

---

Cancer Type	Characteristics	Background
Colorectal Cancer (CRC)	The 2nd most common cancer in women and 3rd most common in men	<ul style="list-style-type: none"><li>• Five-year survival rate is 63%</li><li>• 500.000 newly diagnosed cases every year in Europe</li></ul>
Ovarian Cancer	“The silent killer”	<ul style="list-style-type: none"><li>• Five-year survival rate is 46%</li><li>• 68.000 newly diagnosed cases every year in Europe</li></ul>
Pancreatic Cancer	The deadliest cancer “the lowest survival rate”	<ul style="list-style-type: none"><li>• The lowest five-year survival rate of all cancers, 3%</li><li>• 133.000 newly diagnosed cases every year in Europe</li></ul>



# A strong Clinical and Commercial partner base supports commercialization

## Group 1 Clinical trials Partners



## Group 3 Patient societies



## Group 5 Patient stratification partners



## Group 2 Academic + Technical Partners




## Group 4 Commercial Partners / Sales Channels




- because cancer patients are individuals

# HIGHLIGHTS 2019



# Highlights 2020

---



- because cancer patients are individuals



**European IndiTreat® Market**

## 2cureX operates in a highly attractive market



SEK 12  
billion

Total available market for IndiTreat® testing in Europe

Colorectal cancer  
Ovarian cancer  
Pancreatic cancer

700.000 new  
cases per year

- because cancer patients are individuals

**2cureX**



**European IndiTreat® Market**

## IndiTreat® patents issued in major global markets




- because cancer patients are individuals



# IndiTreat® Market Opportunities beyond Europe

	Colorectal cancer	Ovarian cancer	Pancreatic cancer
Europe	499.667	67.771	132.559
Asia	957.896	153.076	214.499
North America	179.771	27.194	56.002
Total	<b>1.637.334</b>	<b>248.041</b>	<b>403.060</b>



----- Europe



----- Asia



----- North America

- because cancer patients are individuals

Data source:  
Globocan 2018  
(<http://gco.iarc.fr>)





# LAUNCH IN H2 2020

---

## Commercial Partnerships

- *Signed first Distributor agreements*
- *Customer mapping / Salesfunnel*
- *Relationship building*

## IndiTreat® Clinical Program

- *Recruitment pts studies (CRC)*
- *Investigator management*
- *KOL Development*

## IndiTreat® Early Access

- *Internal processes/Logistics*
- *Customer Experience*
- *Customer Interactions*

**Launch  
IndiTreat®**

*Expanding Markets*

*Additional Cancers*


*Partnerships*

*Market access*

*Patient stratification*


- because cancer patients are individuals

# Solid Commercialization roadmap with a strong clinical foundation



- because cancer patients are individuals

# Automation will help increase the availability of IndiTreat®



# The 2cureX Management Team



**Ole Thastrup**  
Founder

**Chief Executive  
Officer**



**Carit  
Andersen**

**Chief Finance  
Officer**



**Grith Hagel**  
Founder

**Head of Project  
Management**



**Maarten van  
der Linden**

**Chief Business  
Officer**



**Henrik Harling**

**Chief Medical  
Officer**



**Jürgen Kupper**

**Managing Director  
2cureX GmbH**

- because cancer patients are individuals

## Highly experienced board



**Povl André  
Bendz**

**Finance**

**Chairman**



**Camilla Huse  
Bondesson**

**Medtech**



**Jørgen Dreyer**

**Drug  
discovery**



**Nils Brünner**

**Oncology  
Innovation**



**Michael Lutz**

**Marketing of  
IVD solutions**



**Ole Thastrup**

**Founder  
  
Biotech  
management**





## Why invest in 2cureX ?

- *A rapidly growing interest in the market for Functional Precision Medicine*
- *Geared for commercial launch of IndiTreat in H2 2020*
- *2cureX wants to launch IndiTreat® in more markets and diseases than first anticipated*
- *To increase penetration into Europe and beyond 2cureX has launched an automation project*
- *Strong financial situation*

- because cancer patients are individuals

**2cureX**